Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

Autor(es):Mostrar menos -

da Costa, Alexandre A. B. A. ^[1] ; do Canto, Luisa M. ^{[2, 3]} ; Larsen, Simon Jonas ^[4] ; Goncalves Ribeiro, Adriana Regina ^[1] ; Stecca, Carlos Eduardo ^[1] ; Petersen, Annabeth Hogh ^[4] ; Aagaard, Mads M. ^[4] ; de Brot, Louise ^[5] ; Baumbach, Jan ^[6] ; Baiocchi, Glauco ^[7] ; Achatz, Maria Isabel ^[8] ; Rogatto, Silvia Regina ^[3]

Afiliação do(s) autor(es)

^[1] AC Camargo Canc Ctr, Dept Med Oncol, Rua Prof Antonio Prudente 211, BR-01509010 Sao Paulo - Brazil

^[2] AC Camargo Canc Ctr, CIPE, Sao Paulo - Brazil

^[3] Univ Southern Denmark, Inst Reg Hlth Res, Dept Clin Genet, Vejle Hosp, Vejle - Denmark

^[4] Univ Southern Denmark, Dept Math & Comp Sci, Odense - Denmark

^[5] AC Camargo Canc Ctr, Dept Pathol, Sao Paulo - Brazil

^[6] Tech Univ Munich, TUM Sch Life Sci Weihenstephan, Chair Expt Bioinformat, Munich - Germany

^[7] AC Camargo Canc Ctr, Dept Gynecol Oncol, Sao Paulo - Brazil

^[8] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BMC CANCER; v. 19, MAY 6 2019.
• Citações Web of Science: 0

Resumo

BackgroundOvarian carcinomas presenting homologous recombination deficiency (HRD), which is observed in about 50% of cases, are more sensitive to platinum and PARP inhibitor therapies. Although platinum resistant disease has a low chance to be responsive to platinum-based chemotherapy, a set of patients is retreated with platinum and some of them are responsive. In this study, we evaluated copy number alterations, HR gene mutations and HR deficiency scores in ovarian cancer patients with prolonged platinum sensitivity.MethodsIn this retrospective study (2005 to 2014), we selected 31 patients with platinum resistant ovarian cancer retreated with platinum therapy. Copy number alterations and HR scores were evaluated using the OncoScan (R) FFPE platform in 15 cases. The mutational profile of 24 genes was investigated by targeted-NGS.ResultsThe median values of the four HRD scores were higher in responders (LOH=15, LST=28, tAI=33, CS=84) compared with non-responders (LOH=7.5, LST=17.5, tAI=23, CS=47). Patients with high LOH, LST, tAI and CS scores had better response rates, although these differences were not statistically significant. Response rate to platinum retreatment was 22% in patients with CCNE1 gains and 83.5% in patients with no CCNE1 gains (p=0.041). Furthermore, response rate was 54.5% in patients with RB1 loss and 25% in patients without RB1 loss (p=0.569). Patients with CCNE1 gains showed a worse progression free survival (PFS=11.1months vs 3.7months; p=0.008) and a shorter overall survival (OS=39.3months vs 7.1months; p=0.007) in comparison with patients with no CCNE1 gains. Patients with RB1 loss had better PFS (9.0months vs 2.6months; p=0.093) and OS (27.4months vs 3.6months; p=0.025) compared with cases with no RB1 loss. Four tumor samples were BRCA mutated and tumor mutations were not associated with response to treatment.ConclusionsHR deficiency was found in 60% of our cases and HRD medium values were higher in responders than in non-responders. Despite the small number of patients tested, CCNE1 gain and RB1 loss discriminate patients with tumors extremely sensitive to platinum retreatment. (AU)

• Processo FAPESP: 08/57887-9 - Instituto Nacional de Oncogenômica
• Beneficiário: Luiz Paulo Kowalski
• Modalidade de apoio: Auxílio à Pesquisa - Temático